Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Phase II Study on the Efficacy and Safety of Cardenilimab Combined With Chemotherapy in the Conversion Therapy of Locally Advanced Esophageal Squamous Cell Carcinoma.

NCT06165380 is registered in ClinicalTrials.gov with Li Zhang as lead sponsor.

NCT NCT06165380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06165380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Phase II Study on the Efficacy and Safety of Cardenilimab Combined With Chemotherapy in the Conversion Therapy of Locally Advanced Esophageal Squamous Cell Carcinoma.
Lead sponsor
Li Zhang
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 23, 2023
Completion date
December 31, 2026
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, neoadjuvant therapies